US-JAPAN HBD EAST Think Tank Meeting 2025

Date: Wednesday, September 17th, 2025, 9:30 AM- 6:00 PM (JST) Venue: Sapporo Convention Center (https://www.sora-scc.jp/eng/access.html) Language: English & Japanese (simultaneous interpretation)

Moderator: IWAMOTO Shin, NORO Erika (PMDA)

					AMOTO Shin, NORO Erika (PMDA)			
	Session	Chair	Agenda items	Times	Speakers and Panelists			
A	Welcome 9:30-9:55		(A-1) From MHLW	5	NOMURA Yumiko Director, Medical Device Evaluation Division, Ministry of Health, Labour and Welfare (MHLW)			
			(A-2) From PMDA	5	NAKAI Kiyohito Chief Safety Officer, Pharmaceuticals and Medical Devices Agency (PMDA)			
			(A-3) From FDA	5	Michelle Tarver, Center Director, the Center for Devices and Radiological Health (CDRH), U.S. Food & Drug Administration (FDA)			
			(A-4) From JFMDA	5	MIYATA Masahiko Vice Chairman, The Japan Federation of Medical Devices Associations (JFMDA)			
			(A-5) From AdvaMed (AMDD)	5	Janet Trunzo Senior Advisor to the President, Senior Executive Vice President, Technology & Regulatory Affairs, AdvaMed			
В	Keynote lecture 9:55-10:30	Robert Thatcher (Diaxamed, LLC),	(B-1) Japanese initiatives to promote medical device development	15	SUZUKI Yuka (Clinical Research, Innovation and Education Center, Tohoku Univ. Hospital (CRIETO))			
		KATAYAMA Hiroshi	(B-2) HBD history and global lessons learned	15	Mitchell Krucoff (Duke Univ.)			
		(National Cancer Center Hospital)	(B-3) Q&A	5				
С	Update on HBD activities 10:35-10:45	UCHIDA Takahiro (Sanamedi, Inc.)	(C-1) Update on HBD activities (2020 – 2025)	10	NAKAGAWA Makoto (PMDA)			
Break (15min)								
D	HBD activities to advance pediatric	YASUKOCHI Satoshi	(D-1) HBD for Children - Achievements and future directions	10	SASAGAWA Kaoru (PMDA)			
	device development and access 11:00-12:10	(Aizawa hospital), Nicole Ibrahim (Mansfield	(D-2) Considerations in Japanese academia in advancing pediatric medical device development: Insight from Japan's Agency for Medical Research and Development	10	FUJII Takanari (SHOWA Medical Univ. Hospital)			
		Fellow)	(D-3) Japanese research projects and regulatory initiatives to promote pediatric/orphan medical device access	10	ANDO Mariko (MHLW)			
			(D-4) What else is needed to advance pediatric medical device development? Industry perspective	10	Dali Alarian (Renata Medical)			
			(D-5) Panel discussion: Breaking barriers: Driving cross-sector collaboration and increased global access	30	Speakers & Sung-Hae Kim (Shizuoka Children's Hospital) SUZUKI Yuka (CRIETO) Eric Chen (Abbott Medical) Nicole Gillette (FDA) TAKAHASHI Sara (MHLW)			

	Session	Chair	Agenda items	Times	Speakers and Panelists				
	Lunch Break (60 min)								
Е	HBD activities to	IKENO	(E-1) Regulatory updates: Japan	10	KOIKE Kazuhisa (PMDA)				
	advance smart	Fumiaki	(E-2) Regulatory updates: US	10	Ken Cavanaugh (FDA)				
	development of SaMD	((E-3) Initiatives to support the	10	TAKAYAMA Masumi (Ministry of				
	13:10-14:20	Univ.),	expansion of Japanese medical		Economy, Trade and Industry)				
	13.10 11.20	KOIKE Kazuhisa	devices into overseas markets:						
		(PMDA)	Japanese ministry perspective (E-4) Considerations in international	10	TADA Tomohiro (AI Medical Service				
		(TWD/T)	development of digital health	10	Inc.)				
			technologies		inc.)				
			(E-5) Panel discussion: Global	30	Speakers &				
			strategies to accelerate SaMD		IKEDA Koji (CRIETO)				
			development: perspectives from		OTAKE Masanori (GE HealthCare				
			industry, academia, and government		Japan)				
F	Challenges and	IWAMOTO	(F-1) The current situation and future	10	SHIBA Takeshi (PMDA)				
	solutions when	Shin (PMDA),	direction of utilization of real-world						
	building multi- national registries	Kenneth	clinical evidence for regulatory decision-making						
	14:25-15:35	Cavanaugh (FDA)	(F-2) Experiences with regulatory use	10	IWAISHI Chie (Edwards				
	11.20 10.00	(FDA)	of registry data: Industry perspective	10	Lifesciences)				
			(F-3) Consideration and future	10	Aaron Lottes (Purdue Univ.)				
			opportunities identified through the		,				
			utilization of real-world evidence						
			(F-4) Deciding whether a registry	10	NAKAMURA Masato (Toho Univ.)				
			should go global: Japanese academic						
			perspective (F-5) Panel Discussion: Opportunities	30	Speakers &				
			for further global alignment of real-	30	YOKOI Hiroyoshi (Fukuoka Sanno				
			world evidence collection and		Hospital)				
			application		Misti Malone (FDA)				
					YASUHARA Daiki (Medtronic				
					JAPAN)				
Break (15min)									
G	Shaping forward-	Mitchell	(G-1) Addressing key bottlenecks in	10	SENSHU Kazuhisa (Terumo				
	looking	Krucoff (Duke	global medical device development:		Corporation)				
	collaboration among	Univ.),	challenges and strategic solutions (G-2) Lessons from success:	10	IKEDA Koji (CRIETO)				
	stakeholders for	YABANA Naoyuki	(G-2) Lessons from success: Rethinking collaboration among	10	IKEDA KUJI (CKIETO)				
	more efficient	(PMDA)	stakeholders in medical device						
	global medical	(11111111)	innovation						
	device		(G-3) Initiatives to accelerate medical	10	Kenneth Cavanaugh (FDA)				
	development		device access: US regulatory						
	15:50-17:10		perspective	1.0	Let Describe LOW (II 13 or				
			(G-4) Initiatives to accelerate medical device access: Singapore regulatory	10	Lai Peng LOW (Health Sciences				
			perspective		Authority, Singapore)				
			(G-5) Panel discussion: Envisioning	40	Speakers &				
			global collaboration in medical device		IKENO Fumiaki (Stanford Univ.)				
			development - a 10-year outlook from		MORIKAWA Satoshi (Boston				
			industry, academia, and government		Scientific Japan)				
					NAKAI Kiyohito (PMDA)				
					Rolf Oberlin Hansen (Danish				
**	CI :				Medicines Agency)				
Н	Closing remarks			5	YABANA Naoyuki (PMDA)				